Biomarkers and prognostication in traumatic brain injury

Abstract

A number of patients who suffer from mild head injury later on develop significant disabilities. Biomarkers help identify and quantify the extent of injury and help predict the possible functional outcome of the patients. There are promising candidate biomarkers for axonal injury (Tau) and astrocytic damage (glial fibrillary acidic protein and S100β) in traumatic brain injury. However, the biological significance of these markers cannot be confidently declared due to lack of studies with adequate sample size.

Keywords

Biomarkers - prognostication - traumatic brain injury

• REFERENCES

• 1 Williams WH, Potter S, Ryland H. Mild traumatic brain injury and Postconcussion syndrome: A neuropsychological perspective. J Neurol Neurosurg Psychiatry 2010; 81: 1116-22
• 2 Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol 2013; 246: 35-43
• 3 Barkhoudarian G, Hovda DA, Giza CC. The molecular pathophysiology of concussive brain injury. Clin Sports Med 2011; 30: 33-48 vii–iii
• 4 Tang-Schomer MD, Patel AR, Baas PW, Smith DH. Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration. FASEB J 2010; 24: 1401-10
• 5 Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-44
• 6 Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol 1999; 101: 211-21
• 7 Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I. et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006; 63: 1277-80
• 8 Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O. et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995; 4: 311-7
• 9 Buttram SD, Wisniewski SR, Jackson EK, Adelson PD, Feldman K, Bayir H. et al. Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: Effects of moderate hypothermia. J Neurotrauma 2007; 24: 1707-17
• 10 Shiozaki T, Hayakata T, Tasaki O, Hosotubo H, Fuijita K, Mouri T. et al. Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 2005; 23: 406-10
• 11 Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG. et al. C-tau biomarker of neuronal damage in severe brain injured patients: Association with elevated intracranial pressure and clinical outcome. Brain Res 2002; 947: 131-9
• 12 Ost M, Nylén K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelsö C. et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006; 67: 1600-4
• 13 Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: Diagnosis and effects of repetitive head trauma. PLoS One 2012; 7: e33606
• 14 Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg 1996; 10: 471-6
• 15 Czeiter E, Mondello S, Kovacs N, Sandor J, Gabrielli A, Schmid K. et al. Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J Neurotrauma 2012; 29: 1770-8
• 16 Olsson A, Csajbok L, Ost M, Höglund K, Nylén K, Rosengren L. et al. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol 2004; 251: 870-6
• 17 Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP. et al. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma 2013; 30: 946-57
• 18 Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B. et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007; 33: 255-60
• 19 Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome. J Neurotrauma 2004; 21: 1553-61
• 20 Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T. et al. GFAP and S100B are biomarkers of traumatic brain injury: An observational cohort study. Neurology 2010; 75: 1786-93
• 21 Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma 2008; 65: 778-82
• 22 Nylén K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgård B. et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 2006; 240: 85-91
• 23 Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C. et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004; 62: 1303-10
• 24 Bulut M, Koksal O, Dogan S, Bolca N, Ozguc H, Korfali E. et al. Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results. Adv Ther 2006; 23: 12-22
• 25 Kövesdi E, Lückl J, Bukovics P, Farkas O, Pál J, Czeiter E. et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien) 2010; 152: 1-17
• 26 Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J. et al. aII-spectrin breakdown products (SBDPs): Diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma 2010; 27: 1203-13